AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 251 min read$PGEN

Tennant Phil sold $594K of PGEN

Tennant Phil (Chief Commercial Officer) sold 79,166 shares of PRECIGEN, INC. (PGEN) at $7.50 ($0.59M total) on 2026-08-25 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Tennant Phil
Published Aug 25, 2026, 9:25 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 25, 2026, 9:30 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$PGEN
Neutral
medium confidence
Mentioned
$PGEN
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PGENNeutralLow
01

Why it matters

Provides fresh data on insider holdings; limited trading relevance.

02

Market read

Routine insider sale with modest size; minimal market impact.

03

What to watch

Potential upcoming financing or strategic moves not disclosed.

Relevance 4/10Novelty 4/10Timing: on filing date 2026-08-25

Background

Form 4 filing discloses insider transactions required by SEC.

Company-level read

Ticker impact

$PGENNeutralMedium confidence
Context

Chief Commercial Officer sold 79,166 shares for $593,745 via a 10b5-1 plan on 2026-08-25.

Expected impact

Limited short-term price pressure; unlikely to move beyond normal volatility.

Evidence & confidence

Sale amount is under $1M and follows a pre‑arranged plan, reducing informational value.

Market effects

Sector

No material impact on biotech sector.

Regional

None.

Global

None.

Counterpoint

What could challenge this read

Sale could be unrelated to company outlook; may be liquidity need.

Key entities

  • Company
    Precigen, Inc.

    Biotech firm listed on NASDAQ under ticker PGEN.

  • Insider
    Tennant Phil

    Chief Commercial Officer of Precigen.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

PGEN insider trading history →

Related articles

AUG 21
$MRNAHighAI 9/10

After Moderna’s Big News, Here Are Three Biotechs to Watch

Moderna (MRNA) and Merck (MRK) rose sharply after positive Phase 3 trial data for a skin cancer therapy. Biotech sector, up 40% YTD, saw gains. Aurinia (AUPH) settled litigation with Teva (TEVA), removing uncertainty. Ocular (OCUL) received positive analyst ratings. Precigen (PGEN) reported strong Q2 revenue and expects cash flow breakeven by year-end.

pro.thestreet.com3 min
AUG 12
$PGENMed

Precigen (PGEN) Q2 2026 Earnings Call Transcript

Precigen (PGEN) reported Q2 2026 PAPZIMEOS net revenue of $53.1 million, up 145.8% sequentially from $21.6 million, and first quarterly net income of $20.1 million, or $0.05 per diluted share. Gross margin was 95% but management expects normalization to high 80% to low 90%. Cash and investments were $38.7 million at June 30, 2026.

fool.com6 min
AUG 4
$PGENMed

PRECIGEN, INC. (PGEN): Results of Operations and Financial Condition

PRECIGEN, INC. (PGEN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Precigen Reports Second Quarter 2026 Financial Results Highlighted by Accelerating PAPZIMEOS Revenue Growth · PAPZIMEOS ® net revenue of $53.1 million in the second quarter of 2026, more than double the prior quarter, reflects accelerating commercial momentum and bro

SEC EDGAR 8-K6 min
JUN 1
$PGENMedAI 9/10

Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years

Precigen (Nasdaq: PGEN) reported updated long-term durability data for PAPZIMEOS (zopapogene imadenovec-drba) in adults with recurrent respiratory papillomatosis. According to the company, 15 of 18 complete responders (83%) had ongoing complete responses for at least 36 months as of April 30, 2026, with 5 beyond 4 years; median duration not yet reached and no new safety events were observed. The FDA granted seven-year orphan drug market exclusivity.

newswise.com4 min